Adlai Nortye Ltd.
NASDAQ: ANL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yang Lu
- Employees
- 123
- Headquarters
- Grand Cayman, Cayman Islands
- IPO year
- 2023
- Market cap
- $583.3M
- Website
- https://www.adlainortye.com
Loading ANL…
Loading profile data…Frequently asked questions about ANL
What does Adlai Nortye Ltd. (ANL) do?
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastati...
Where does ANL trade?
Adlai Nortye Ltd. (ANL) trades on the NASDAQ Global Market.
What sector is ANL in?
Adlai Nortye Ltd. (ANL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Adlai Nortye Ltd.?
Yang Lu is the chief executive officer of Adlai Nortye Ltd. (ANL).
Where is Adlai Nortye Ltd. headquartered?
Adlai Nortye Ltd. is headquartered in Cayman Islands.
Does ANL pay a dividend?
Adlai Nortye Ltd. (ANL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ANL go public?
Adlai Nortye Ltd. (ANL) completed its initial public offering in 2023.
Is ANL an ADR?
Yes — ANL is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Adlai Nortye Ltd. reporting and dividends follow the underlying issuer.